Although both obesity and smoking are major preventable causes of disease and premature death (1, 2), smokers are generally leaner than nonsmokers (3, 4) , and weight gain is a common unwelcome by-product of smoking cessation (5, 6) . The mechanisms by which smoking affects body weight are incompletely understood but are thought to involve the ability of nicotine to block the hypothalamic cannabinoid receptors that are known to be involved in the regulation of appetite and satiation (7) . Thus, if smoking and smoking cessation are causally associated with body weight, one would expect other nicotine-containing products to have comparable associations with body weight.
In previously published meta-analyses of genome-wide association studies, an association was identified between a genetic variant (rs1051730) localized to the nicotinic acetylcholine receptor subunit alpha-3 gene (CHRNA3) and smoking quantity in smokers (8) (9) (10) (11) (12) (13) (14) (15) . In white Europeans (www.hapmap.org), the rs1051730 single-nucleotide polymorphism is in strong linkage disequilibrium (r 2 = 1.0, D′ = 1.0) with the genetic variant rs16969968, encoding an amino acid change previously shown to affect receptor function (16) . In a subsequent metaanalysis, Freathy et al. (17) used a heterogeneity test to infer an interaction between the rs1051730 single-nucleotide polymorphism and smoking status on body mass index (BMI), although no formal pairwise test of interaction was performed.
In the present study, we sought to replicate the previously observed associations between rs1051730 and smoking quantity and to examine whether the rs1051730 variant modifies the relationship of smoking with BMI through a formal test of interaction. In secondary analyses, we explored whether another nicotine-containing product, snus (an oral moist tobacco commonly used in Scandinavian countries), yielded results similar to those for smoking. We examined snus because it contains amounts of nicotine comparable to that in cigarettes and elicits detectable stimulatory effects on the brain (7, 18 ), yet it might, compared with smoking, be differentially associated with potential confounders such as education, diet, alcohol consumption, and physical activity.
MATERIALS AND METHODS

Study participants
The Gene-Lifestyle Interactions and Complex Traits Involved in Elevated Disease Risk (GLACIER) Study is a prospective, population-based cohort study nested within the Västerbotten Health Survey in northern Sweden (19) . Baseline examinations were performed from 1985 through 2004. Participants were invited to attend an examination on their 40th, 50th, and 60th birthdays. Clinical characteristics (age, sex, height, and weight) were collected, and detailed assessments of lifestyle were obtained through the use of a validated questionnaire (19, 20) . All participants provided written informed consent as part of the Västerbotten Health Survey, and ethical approval for the GLACIER Study was obtained from the Regional Ethical Review Board in
Umeå. From those with data at the first visit (n = 17,486), participants not genotyped for rs1051730 (n = 744), participants with self-reported diabetes (n = 312), and participants for whom we lacked data crucial to the analyses (n = 4) were excluded. Thus, the total number of individuals included in our analyses was 16,426.
Clinical measures
Weight (to the nearest 0.1 kg) and height (to the nearest centimeter) were measured with a calibrated balance-beam scale and a wall-mounted stadiometer, respectively. BMI was calculated as weight (kg)/height (m) 2 . Current smokers were defined as people who reported daily smoking; participants who had never smoked or who smoked occasionally were considered never smokers (21) . Participants who reported having quit smoking were considered former smokers. We also refer to a group of ever smokers, composed of current and former smokers. The same classifications were applied to snus use.
In the analysis in which we sought to replicate the main association between rs1051730 and smoking quantity, information on cigarette quantity was available as a categorical variable (1-4, 5-14, 15-24, or >24 cigarettes/day). This variable was available in a subgroup consisting of 5,304 current and former smokers.
Comparison of putative confounders
To determine whether smoking and snus have comparable relationships with putative confounding variables, we conducted Pearson correlation analyses between smoking and snus separately with educational level (6) (7) years of compulsory school education, compulsory school plus college, or compulsory school plus college plus university), leisure-time physical activity level (never, occasionally, 1, 2-3, or >3 times per week), alcohol consumption (0, 1-4, 5-10, or >10 g of ethanol/day), and a healthy diet score. The diet score was constructed from intakes of 8 food groups (whole grains, fish, fruits, and vegetables were designated as favorable foods, whereas red and processed meats, sweets, sugared beverages, and fried potatoes were designated as unfavorable), as previously described (22) . Intakes for each food group were categorized into quartiles and
given ascending values of 0, 1, 2, 3 for favorable foods and descending values of 3, 2, 1, 0 for unfavorable foods. These values were summed to generate a diet score of 0-24, with higher scores indicating a healthier diet (22) .
Genotyping
DNA was extracted from peripheral white blood cells, and genomic DNA samples were diluted to 4 ng/μL, as previously described (23, 24) . The rs1051730 variant was genotyped with the OpenArray SNP Genotyping System (BioTrove, Inc., Woburn, Massachusetts) at the Harvard School of Public Health, Boston, Massachusetts. The genotyping success rate was higher than 98%, and within the study sample the genotype frequencies were in Hardy-Weinberg equilibrium (P = 0.97). The rs1051730 variant harbors alleles C (major) and T (minor) on the forward strand. The genotyping was done on the reverse strand in GLACIER, but to facilitate interpretations and comparisons of results, we report the corresponding forward strand alleles, in agreement with Freathy et al. (17) . (17), the exposure of smoking was categorized by strata of never and ever smokers, and separate regression models were run within these strata to generate effect estimates and P values.
Statistical methods
Power calculations were made in Quanto, version 1.2.4 (written by John Morrison and W. James Gauderman;
http://hydra.usc.edu/gxe). In the article by Freathy et al. (17) , heterogeneity tests (Cochran's Q statistics and I2 tests) were used to infer interactions, but no formal test of interaction was reported. Therefore, we undertook both tests of heterogeneity and formal pairwise interaction tests, with the caveat noted that the test of heterogeneity is unreliable when few strata are compared. Our heterogeneity test included the comparison of effect estimates and standard errors for the association between rs1051730 and BMI among strata of smoking status. Fixed-effects meta-analysis was performed with the "metan" module in Stata (27) .
We also assessed heterogeneity in never smokers and ever smokers between the meta-analysis of Freathy et al. (17) and the GLACIER cohort. Finally, we meta-analyzed the results from the GLACIER Study with those from the meta-analysis reported by Freathy et al. (17) . We included interaction terms for smoking status and rs1051730 (smoking status × rs1051730) in linear models to evaluate whether the associations of the singlenucleotide polymorphism on BMI differed in magnitude by strata of smoking status. Finally, we repeated the analyses outlined above with snus use in place of smoking status.
RESULTS
Participant characteristics are shown in Table 1 .
Association of tobacco use and BMI
Smoking status and BMI were inversely related (β = −0.46 kg/m 
Association between rs1051730 and smoking or snus
The rs1051730 variant was positively associated with category of smoking quantity (β = 0.08, SE = 0.01; P < 0.0001). The rs1051730 variant was not associated with smoking status (P > 0.05) or with snus use (P > 0.05)
Interaction between rs1051730 and smoking on BMI
The BMI means and 95% confidence intervals per strata of genotype, smoking, and snus use are shown in never users). Additional adjustment for snus use or potential confounders (as listed in Table 3 ) did not materially affect these results (P interaction = 0.60 and P interaction = 0.18, respectively). Repeating the above analyses with occasional smokers and former occasional smokers excluded from the group of never smokers did not materially affect the results.
Interaction between rs1051730 and snus on BMI
There was no statistically significant interaction between snus use and the rs1051730 genotype (P interaction = 0.89 for current vs. never andP interaction = 0.87 for ever vs. never users). Additional adjustment for potential confounders (as listed in Table 3 Table 4 .
Heterogeneity tests and meta-analysis
To recapitulate the analysis of Freathy et al. (17) , we conducted Cochran's Q test to assess whether genotype modified the association of smoking with BMI. The test of heterogeneity between ever and never smokers was not statistically significant within GLACIER (P = 0.28, I 2 = 13.8%).
We conducted heterogeneity tests between the cohort of Freathy et al. (17) and the GLACIER cohort within the never smoker and ever smoker strata. The test of heterogeneity between the 2 cohorts was not statistically significant in never smokers (P = 0.21, I 2 = 35%) or in ever smokers (P = 0.43, I 2 = 0%). By contrast, significant heterogeneity was observed between never smokers and ever smokers in the meta-analysis (n = 40,626) comprising summary statistics from Freathy et al. (17) and the GLACIER cohort (P < 0.001, I 2 = 93%).
DISCUSSION
In an attempt to replicate previous reports (8-14, 17), we examined the associations between the CHRNA5-CHRNA3-CHRNB4 rs1051730 variant and smoking and BMI. In line with previous results, the rs1051730 variant was positively associated with smoking quantity in the GLACIER Study. We also followed up on a prior report of interaction between the rs1051730 variant and smoking status in relation to BMI (17) . Consistent with the initial report, the association of the rs1051730 variant with BMI was statistically significant in current and former smokers, with an effect estimate approximately 3-fold larger in magnitude than in never smokers;
however, the formal test of interaction was not statistically significant. Thus, we conclude that although there is tentative evidence of an interaction between smoking and the rs1051730 variant in our data on the basis of the smoking stratum-specific results, the formal test of interaction did not confirm that these stratumspecific effect estimates differed in magnitude.
It should be noted that where formal cohort-specific interaction test statistics are unavailable, inasmuch as the tests can be performed by pooling and comparing the main effect test statistics from each cohort by strata of the putative effect modifier. In general, it is likely that this approach to inferring interaction effects will yield a P value similar to that of the conventional pairwise test of interaction; indeed, in our study, both approaches yielded comparable P values. However, in some scenarios-for example, where measurement error (a source of heterogeneity) is greater in one stratum than the other-the results from the 2 approaches can differ, with the heterogeneity test result being the least accurate. The conventional pairwise test of interaction also has the advantage of yielding interaction and marginal effect coefficients, which are useful for determining the clinical relevance of an interaction effect and for subsequent power calculations.
A statistically significant interaction might be absent in GLACIER because our study is underpowered to replicate the interaction reported by Freathy et al. (17) ; however, Freathy et al. did not report an interaction effect estimate in their article, so we could make power calculations only on the basis of a range of plausible effect estimates (see Appendix Table 1) . If the interaction effect estimate reported here is accurate, future studies will require a cohort of approximately 72,000 persons with characteristics similar to participants in GLACIER to confirm or refute an interaction of the same magnitude between smoking and the rs1051730 variant on BMI with a power of 80%.
In the present study, we identified an inverse association between smoking and BMI and a positive association between snus use and BMI. These findings are compatible with those reported elsewhere. As shown in Table 3 , the correlation coefficients differ in magnitude and sometimes direction between smoking status or snus use and the putative confounders, which supports our hypothesis that although cigarettes and snus share the factor that is believed to be causally related with obesity (i.e., nicotine), they do not share the same confounding factors in this population. Although it is possible that cigarettes contain active substances absent from snus that drive the interactions described above, it seems more plausible that it is the obesogenic correlates of snus (i.e., confounders) that underlie the association of snus with obesity, rather than a direct causal effect of snus. Unlike cigarette smoking, which is common in almost all populations, snus use is confined almost exclusively to Sweden and Norway; thus, the standard epidemiologic approach of comparing effect estimates across populations, which differ in the frequency and distribution of potential confounding factors, to infer causal relationships (33) is not possible in epidemiologic studies of snus use.
In conclusion, we found evidence of association between the CHRNA5-CHRNA3-CHRNB4 rs1051730 variant and smoking quantity but not status. The association of the rs1051730 variant with BMI was statistically significant in the overall study population, and the effect estimate was considerably larger in current and former smokers than in never smokers; however, the pairwise test of interaction between this variant and smoking status or snus use on BMI was not significant in GLACIER. By contrast, the effect estimate was statistically significant only in never snus users, not in current or former snus users, and additional adjustment for smoking status ablated the association. These findings tend to suggest that the observed associations and tentative interaction effect of smoking with BMI are likely to be explained by factors other than nicotine, which is unique to smoking tobacco products or smoking-related behaviors. Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index; n, number of participants. P values are based on linear regression models, marginal effects were tested by fitting genotype as the independent variable (coded assuming an additive effect of the modeled allele) with BMI.
